5/13
09:15 am
trvi
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Neutral
Report
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/9
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming Conferences
High
Report
Trevi Therapeutics to Participate in Upcoming Conferences
5/8
10:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
5/7
04:19 pm
trvi
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
5/7
04:05 pm
trvi
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
5/1
04:21 pm
trvi
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024 [Yahoo! Finance]
5/1
04:05 pm
trvi
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Medium
Report
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
4/9
08:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
4/9
07:39 am
trvi
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference [Yahoo! Finance]
4/9
07:30 am
trvi
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Medium
Report
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
4/4
07:49 am
trvi
Trevi Therapeutics to Participate in Upcoming April Events [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming April Events [Yahoo! Finance]
4/4
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming April Events
Medium
Report
Trevi Therapeutics to Participate in Upcoming April Events
4/3
05:48 pm
trvi
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market to Exhibit Immense Growth at a CAGR of 4.9% by 2034 | DelveInsight [Yahoo! Finance]
4/2
07:39 am
trvi
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team [Yahoo! Finance]
Low
Report
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team [Yahoo! Finance]
4/2
07:30 am
trvi
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Low
Report
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
3/21
09:37 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $9.00 price target on the stock.
3/21
08:06 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
3/20
04:16 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
High
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
3/20
04:05 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
3/13
04:05 pm
trvi
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
Medium
Report
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024